Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 200 of 741 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/01/21
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 12/31/13
End: 09/26/16
Due: 09/26/17
Phase: N/A
Priority: Normal
Start: 05/21/12
End: 10/01/18
Due: 10/01/19
Phase: N/A
Priority: Normal
Start: 10/31/07
End: 12/31/08
Due: 12/31/09
Phase: N/A
Priority: Normal
Start: 12/28/15
End: 05/19/20
Due: 05/19/21
Phase: N/A
Priority: Normal
Start: 06/30/07
End: 12/31/08
Due: 12/31/09
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/03/21
End: 12/01/21
Due: 12/01/22
Phase: N/A
Priority: Normal
Start: 03/26/23
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 02/08/22
End: 03/31/26
Due: 03/31/27
Phase: N/A
Priority: Normal
Start: 07/01/19
End: 07/01/22
Due: 07/01/23
Phase: N/A
Priority: Normal
Start: 04/30/14
End: 06/30/14
Due: 06/30/15
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
Phase: N/A
Priority: Normal
Start: 06/21/19
End: 06/21/26
Due: 06/21/27
Phase: N/A
Priority: Normal
Start: 07/10/17
End: 07/01/18
Due: 07/01/19
Phase: N/A
Priority: Normal
Start: 01/23/18
End: 04/25/18
Due: 04/25/19
Phase: N/A
Priority: Normal
Start: 04/12/16
End: 11/16/18
Due: 11/16/19
Phase: N/A
Priority: Normal
Start: 05/31/15
End: 01/31/16
Due: 01/31/17
Phase: N/A
Priority: Normal
Start: 07/31/11
End: 07/31/12
Due: 07/31/13
Phase: N/A
Priority: Normal
Start: 06/09/21
End: 12/14/25
Due: 12/14/26
Phase: N/A
Priority: Normal
Start: 02/29/08
End: 08/31/08
Due: 08/31/09
Phase: N/A
Priority: Normal
Start: 07/19/17
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 06/30/06
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 01/31/14
End: 08/22/23
Due: 08/22/24
Phase: N/A
Priority: Normal
Start: 06/12/14
End: 01/05/17
Due: 01/05/18
Phase: N/A
Priority: Normal
Start: 11/30/02
End: 10/31/03
Due: 10/31/04